A sample of my pitch-deck writing and related market research for a revolutionary and next-generation micro cardiovascular stent, which incorporates nanotechnology, MEMS, computer controlled surgery algorithms, and MRI. I conducted this work for a client, an inventor and scientist who gave me permission to make this sample public.

1. SAMPLE OF MARKETING
CONSULTING WORK AND
PRESENTATION WRITING FOR
MARKETING PROFESSIONAL &
BUSINESS CONSULTANT –
Clifford M. Thornton
Mobile: 267-524-7144
Email: clifford.thornton@gmail.com

2. ARTERY REPAIR SYSTEMARTERY REPAIR SYSTEM
Bio-Medical Company
This presentation was researched, planned, and written by Clifford M. Thornton
Mobile: 267-524-7144 Email: clifford.thornton@gmail.com

3. • Coronary artery disease (CAD) is the development of atherosclerotic lesions in their
coronary arteries. This is frequently treated with percutaneous intervention (PCI),
which usually involves balloon angioplasty and stent implantation. The
angioplasty procedure works to clear the artery by compacting the plaque and the
stent serves as a scaffold to support and re-enforce the artery, thereby keeping it
open to allow continuous blood-flow.
Key statistics:
• Cardiovascular disease is the leading global cause of death, accounting for 17.3
million deaths per year, a number that is expected to grow to more than 23.6
million by 2030.
• Cardiovascular disease is the No. 1 cause of death in the United States. Over
2,100 Americans die of cardiovascular disease each day, an average of one death
every 40 seconds.
• After age 40, about 50% of men and one-third of women can expect to have
coronary artery disease. This can rapidly evolve into a life-debilitating or life-
threatening condition.
• By 2030, the American Heart Association (AHA) estimates that 40.5% of the US
population will have some form of CVD, with direct costs estimated at $818 billion.
The Problem: Coronary artery disease is the leading
cause of morbidity and mortality in the world.
Coronary stenting is a ubiquitous, clinically accepted
and routinely used procedure to treat it. Drug-eluting
coronary stents (DES) is now the “Gold Standard” in
cardiovascular care.

4. • Coronary artery disease (CAD) is the development of atherosclerotic plaque in the human
coronary arteries; these arteries supply the heart itself with oxygen-rich, life-supporting
blood. A human being can only live about 3 minutes without this continuous blood-
flow. Which is why time is of the essence for this condition and procedure.
• CAD is frequently treated with percutaneous intervention (PCI), which usually involves
balloon angioplasty and stent implantation. The angioplasty procedure works to clear
the artery by compacting the plaque and the stent serves as a scaffold to support and re-
enforce the artery, thereby keeping it open to allow continuous blood-flow.
• A small mesh tube called a stent or bare-metal stent (BMS) is usually placed in the newly
widened part of the artery. The stent holds up the artery and lowers the risk of the artery
re-narrowing. Some stents, called drug-eluting stents (DES), are coated with medicines that
are slowly and continuously released into the artery. DESs are now the standard care.
What is a coronary stent and how is it placed or
implanted in the coronary arteries?
Coronary (Balloon) Angioplasty Coronary Stent Implant Primary drugs used
in drug-eluting stents
(DES):
•Everolimus, a
derivative of sirolimus;
serves as an
immunosuppresant
•Sirolimus also known
as rapamycin which are
produced by the
bacterium streptomyces
hygroscopicus; serves
as an
immunosuppresant
Over 1 million angioplasty procedures performed in U.S. per year and
approximately 454,000 stent implants (45% of procedures) per year.

5. The evolution of interventional cardiology and
related balloon angioplasty and coronary stent
placement has greatly benefited patients, however
interventional cardiologists still seek “the perfect
stent”.
Near-Future: Bio-Compatible stents
will mark the 5th
Revolution in
cardiology as it will herald a new era
given its untethered, and hence
extremely versatile function and
also offers the precision of robotic-
assisted surgery (RAS).

6. The Solution: Artery Repair Apparatus or
biocompatible-stent, fabricated from bio-compatible
(assembled from nano-scale elements), semiconductor
elements, will be the 5th
Revolution in
cardiovascular care, treating complex occlusions and
vessel aneurysms in a way that was not clinically
possible before.
“Sub-12-French devices negating the need for a surgical cutdown (i.e. when the vein is
exposed surgically) could be marketed and sold to a wider customer base.”
•Control guidance of the stents is enabled by the use of Nuclear Magnetic Imaging
technology- ability to reach capillaries in the brain & lower extremities
•This invention has several advantages over prior angioplasty and stenting
technologies, such as being untethered, 100% image guided, and benefits from
the precision of Robotic Assisted Surgery (RAS), which is fully integrated into it.
•Will place endovascular grafts within the human body to the effect of facilitating rapid
delivery (critical in the case of Thoracic Aortic Aneurysms (TAA) and Abdominal Aortic
Aneurysms (AAA)) of a fused stent (patch).
•The stent will be manufactured from bio-compatible semiconductor cells, which will
be used to repair weakened human vessels such as arteries and veins.
•By repairing and supporting weakened artery walls, aneurysms and their clinical
manifestations can be prevented.
•Upon assembly of the stent, this innovative process will detect, control, position,
and fuse the stent(s) by means of Nuclear Magnetic Imaging.

7. Stent Device (AARA)
Endovascular Grafting Stent Fabricated by
Apparatus & Procedure Cells - Customize
Sizes & Shapes
Implanted Stent –
Nuclear Magnetic Cells Manufactured
Resonance (NMR) from Bio-Compatible
Technology Controls Semiconductor Cells
Movement of the Stent
Present Methods
Reinforce Weakened or Require Expert
Abnormally Dilated Vessels Surgeons

8. Stent Device (AARA)
• Repair weakened arteries, vein walls, or other human
body vessels
• Reinforce artery and vein walls
• Utilizes resilient flexible substance inert to bodily
fluids
• Stents are adjustable & expandable
• Based on the radio frequency (RF)
• Can be made smaller or larger (in order to accommodate
vessel size and structure, allowing for ideal placement and
implantation)
• Controlled by magnetic properties, which is very precise

9. The Automated Artery Repair Apparatus (AARA) has
several advantages over existing stent and vascular graft
technologies. It will be a game-changer, as its robotic
assisted surgery capabilities are analogous to the
automobile revolution of driverless cars.
“Advances in robotic surgery and hybrid endovascular and open surgery
techniques will open new frontiers for surgeons.”
Clinical Challenge Angioplasty-Placed Stents Automated Artery Repair Apparatus (AARA)
Angioplasty fails to adequately open
an artery
Stent must be put in-place by the guidewire, but
determining the right-size French catheter takes
time (trial & error).
Since the AARA is deployed directly into the
blood-stream and does not require wire
determination, the stent can be quickly and
efficiently deployed to the effected site
Traditional stents are susceptible to
stent thrombosis and in-stent
restenosis (ISR); there is a 5%
incidence of ISR with drug-eluting
stents and 20-30% with bare-metal
stents. ISR is associated with
significant morbidity.
Drug-eluting stents are marketed to reduce the
thrombosis risk, but risk of in-stent restenosis
persists.
The compound materials which AARA will be
constructed from will resist thrombus formation;
in-stent restenosis of the biocompatible stents is
very unlikely given its nanoscale.
Endothelial (artery wall) Damage
and smooth muscle cell necrosis
(death of cells) and neo-intimal
hyperplasia
Today’s stents have better recoil, allowing for
better placement and image-guided placement
(OCT, IVUS, MRI), however it is not done
routinely; only in a minority of procedures.
AARA placement will be very precise by the
employment of Robotic Assisted Surgery (RAS)
and MRI image-guidance will be used 100% of the
time as it is integrated into the system.
Placement of stents into diabetic
patient presents certain obstacles
and complex decisions
Patients with Diabetes Mellitus may have to
comply with a dual-anti-platelet therapy (DAPT)
and have higher rates of ISR.
The AARA will be developed to address the
diabetic patient; the risk of ISR is negligible.
Difficult-to-stent anatomical areas
such as bifurcations
Placement of BMSs and DESs are difficult in
tortuous arteries and bifurcations as a
cardiologist must navigate these with the
guidewire
AARA will have no difficulty in reaching the
thinnest arteries and will be able to
circumnavigate any vessel or bifurcation given its
nanoscale size and MRI-guidance.
Stent Obstructions Permanent Metallic Stents can cover side
branches and cause overhang at ostial lesions
and inability to graft the stented segment.
Again, given AARA’s nanoscale size, it will not
cover side branches or overhang.

10. Continued: Advantages of the Artery Repair System over
traditional, catheter-deployed stent systems.
Clinical Challenge Angioplasty-Placed Stents Automated Artery Repair Apparatus (AARA)
Coronary imaging requires high
temporal resolution to resolve the
constant motion of the respiratory and
cardiac cycles (i.e. diastole/systole)
and high spatial resolution for the
accurate imaging of very small vessels.
Angiography, the standard imaging in an
angioplasty and stent placement procedure, has
limited capabilities and newer modalities
(Intravascular Ultrasound (IVUS), Computed
Tomography (CT), and Magnetic Resonance
Imaging (MRI) are not routinely used.
AARA will ALWAYS employ the use of image-guided
(MRI) stent-placement as it is integrated into the
system and works seamlessly with robotic-assisted
surgery functionality.
Biomechanical Factors: Persistent
non-physiological stresses inside the
arterial wall or abnormal wall shear
stresses (WSS) caused by a stent-
disturbed hemodynamics that
undermine the correct endothelial
functionality.
Traditional stents are prone to these structural and
hemodynamic problems.
AARA, will cause negligible wall shear stress or any
changes in vessel hemodynamics, due to its
nanoscale size.
The most important geometric
characteristics for a stent are: Length,
Diameter, Strut Thickness, and Mesh
Shape
Thinner stent struts, compounds (i.e. cobalt
chromium, platinum chromium) allow for
improved geometric properties, however they are
still limited by their manufacturer’s factory design,
which is static.
The biocompatible stents have almost limitless
ability to conform to the needs of the obstruction
and corresponding vessel; it is incredibly versatile
and adaptable. It can conform to each unique
situation and form accordingly.
Deeper attention is being paid to
complex geometries such as curved
vessels or coronary bifurcations, in
terms of stenting these difficult areas
Thinner-strutted stents, bioresorbable coronary
scaffolds, and image-guidance address this
challenge, but there are physical limits to what
traditional stents can accomplish.
AARA is the perfect solution to stent placement in
these difficult anatomical areas of vessels as both
their nanoscale size, and precise navigation can
effectively stent all of these areas.
Sub-optimal stent deployment leads to
late adverse events
Until advanced image guidance is utilized routinely
with catheter-based stent placement, optimal
stent placement is unlikely when it is not.
Adverse events when utilizing AARA will be
significantly reduced due to precise and effective
stent placement.

11. Why does the Automated Artery Repair Apparatus employ
Robotic Assisted Surgery (RAS)? What are its advantages
over laparoscopic or traditional surgery?
• The system integrates RAS into its platform because it is more precise, more efficient
and faster to deploy the stent or conduct the artery repair. This technology utilizes
very fast computer processors & related computer software to guide and control
the biocompatible stents or devices. The previous generation of catheters and stents
require skilled surgeons to manually guide & control the devices. With this new system,
the surgeon still directs the surgery, however computer mapping and algorithms offers
optimal navigation routes and placement locations. This represents a huge leap in
technological innovation.
ADVANTAGES OF ROBOTIC ASSISTED SURGERY (RAS):
• Minimally invasive
• Greater visualization
• Precision of the internal surgical work
• Augments the skills of a surgeon
• Enhanced dexterity: extremely fine & precise movements by the biocompatible stents and their
active functions
• Physician looks at the console versus the patient
• More effective surgery equates, clinically, to easier and shorter recovery period, with fewer
complications
• With the aid of computer intelligence, the visualization of a procedure and the support for
surgical movements is becoming more precise.
• Less pain & blood-loss for the patient
• Quicker patient recovery and related shorter hospital length-of-stay (LOS)
• Integrated Surgery: integrate anatomic data (MRI, CT, US); this means better guidance

12. Worldwide Stent Market Size: Coronary &
Vascular Stents: World demand for stents to treat
atherosclerosis is growing, especially in emerging
markets (i.e. India, China, South America) due to a
rising prevalence of cardiovascular disease, an aging
population, and further penetration in emerging
markets.
• The global interventional cardiology and peripheral vascular devices market is expected to reach
$26.72 Billion by 2019 from $18.73 Billion in 2014, at a CAGR of 7.4% from 2014 to 2019.
• U.S. market for coronary stents is forecast to be $5.61 billion by 2020 (BMS/DES)
• Key Emerging Market Sales of coronary stents are $2.3 Billion with projected 7% annual growth
• Global stent sales are forecast to grow at nearly double-digit rates between through 2021
• 59.6% of stent market is comprised of coronary stent sales
Coronary
Stents

13. The Worldwide market share for coronary stents is
concentrated between Abbott Laboratories, Boston
Scientific, and Medtronic, however some new entrants
with cutting-edge solutions are entering the fray and are
pushing the boundaries in stent technology and making
breakthrough Innovations. These innovations include
hybrid (drug-eluting and biodegradable) stents,
bioresorbable coronary scaffolds, and proprietary anti-
platelet drugs, such as Biosensor’s Biolimus A9.
Note: Others include: Microport Scientific (China)-
www.microport.com, Biotronik, Inc. (Germany)-
www.biotronik.com, Sahajanand Medical Technologies
(India)-www.smtpl.com, Elixir Medical Corp. (U.S.)-
www.elixirmedical.com, and Stentys S.A. (France)-
www.stentys.com
Worldwide Coronary Stent Sales by Manufacturer
In Millions of US$
Abbott Laboratories (U.S.)-
www.abbott.com
Boston Scientific (U.S.)-
www.bostonscientific.com
Medtronic Corp. (U.S.)-
www.medtronic.com
Terumo Medical (Japan)-
www.terumomedical.com
Biosensors (Japan &
Singapore)-
www.biosensors.com
Others
2013 Sales 1,375 815 1,780 346 336 784
2014 Sales 1,463 865 1,740 367 324 933
% Change 6.0% 5.8% -2.3% 5.7% -3.7% 16.0%
Total Worldwide Market Value (2014) 5,692

14. As stent technology has evolved, entrenched players as
well as new entrants have developed a wide-range of
stent product systems. Drug-eluting stents (DES) are
now the “gold-standard” of care, however a market
still exists for bare-metal stents (BMS). Along with BMS
and DES, both entrenched and new players are
marketing a plethora of innovative and very clinically
advanced stent solutions.
Coronary Stent Products by Manufacturer
Abbott
Laboratories
Boston Scientific Medtronic Corp.
Terumo
Medical
Biosensors Microport Scientific Biotronik Inc.
Sahajanand
Medical
Technologies
Elixir Medical
Corp.
Stentys S.A.
Bare Metal
Stents (BMS)
Promus Premier
Rebel (PtCr alloy),
VeriFLEX
Integrity BMS Tango, Mustang, Waltz
Flexinnium,
Tetriniun (Cobalt
Chromium Stent)
Self-opposing
BMS- currently
in FDA study
Drug-Eluting
Stents (DES)-
Everolimus,
Sirolimus,
Rapamycin
Xience Alpine
Promus Element,
Promus Premier
(Platinum
Chromium)
Resolute Integrity-
1st and only FDA
approved DES for
Diabetes
Ultimaster
(Sirolimus)
Firehawk (Rapamycin)-
World's 1st & only target
eluting stent (TES),
lowest drug-dosage
Supraflex,
Vactaflex,
Indolimus
(Sirolimus)
DESyne
Drug-Eluting
Stents (DES)-
Paclitaxel
ION
Biodegradable
Polymer Stents
Synergy S-Stent
EveroFlex
(Everolimus)
DESyne BD-
achieves bare-
metal surface
in 6-9 mos.
Coronary Grafts GraftMaster RX
Polymer
Bioresorbable
Vascular Scaffold
(BVS)
Absorb BVS ART
Firesorb Bioresorbable
Target Eluting Coronary
Scaffold System
(Rapamycin)- First-in-
Man
DREAMS
(magnesium
alloy)
DESolve BRS

15. • Vascular stents are required and implanted for the same reason that coronary stents are, that
is to support an artery like a scaffold, once balloon angioplasty has been performed; the
clinical indication is usually atherosclerotic plaque obstructing the artery. Also, just
as drug-eluting coronary stents are deployed, to reduce endothelial damage and speed-up
recover, vascular drug-eluting stents are now available.
• Vascular artery occlusions can have serious implications for a patient including limb
malfunction and poor limb vascularization, which can possibly lead to limb amputation, it can
cause the patient severe pain and difficulty or inability to walk, and it can also effect one’s
venous return or blood-flow, negatively impacting their heart’s filling (diastolic function).
• Vascular stents are placed and implanted just as coronary stents are, with vascular
angioplasty guidewires and balloons, however specified for certain vascular areas; this can
include carotid, iliac, and femoral (above-the-knee (suprapopliteal) or below-the-knee
(infrapopliteal). There are also vascular stents for biliaries, bronchial, renal, and urinary
vessels.
• Vascular grafts are usually needed when a major vascular artery, such as the thoracic aorta
(TA), abdominal aorta (AA) shows evidence of an aneurysm (detected by X-ray, ultrasound
(US), computed tomography (CT), or magnetic resonance imaging (MRI). The risk of a
thoracic (TAA) or abdominal aortic aneurysm (AAA) rupturing can be death (AAAs are one of
the top 10 causes of death for Men in the U.S.).
• Vascular grafts are placed surgically and serve to support the artery, also like a scaffold, but
cover a larger anatomical area than stents, since these arteries are relatively large (around 3.0
– 4.0 CM in diameter). These grafts are then visible in future medical imaging tests.
What clinical situations necessitate implantation
of a vascular stent or endovascular graft? How are
vascular stents guided & implanted?

16. The worldwide Endovascular Graft Devices market is
experiencing very healthy growth as more interventional
options are available to patients with this potentially life-
threatening condition. Also, the occurrence of aortic
aneurysms is increasing worldwide.
• The Worldwide Aortic Stent Grafts Market will be worth $1.9 Billion by 2020 while
growing at a CAGR of 9.5% to 2018 and 6.7% to 2020.
• The U.S. EVAR endograft market, which represents over 50% of the worldwide
market, is currently valued at about $760 million with a CAGR of 8% per year.

17. The worldwide vascular stent & endovascular
grafting market is experiencing faster growth (around
7-8% annually) as compared with the coronary stent
market (4-5% annually). This brisk growth is being
driven by greater awareness and detection of
vascular disease and its implications, new medical
technology to address it (such as below-the-knee
angioplasty & stents), and more disposable income
to pay for these treatments.
Worldwide Vascular Angioplasty, Stent & Endovascular Graft Sales by Manufacturer
In Millions of US$
Abbott Laboratories
(U.S.)-
www.abbott.com
Boston Scientific (U.S.)-
www.bostonscientific.com
Medtronic Corp. (U.S.)-
www.medtronic.com
C.R. Bard, Inc. (U.S.)-
www.crbard.com
Others
2013 Sales 469 809 867 830 370
2014 Sales 527 850 895 928 407
% Change 6.0% 4.8% 3.1% 10.6% 9.2%
Total Worldwide Market Value (2014) 3,608
Note: Others include: Terumo Medical (Japan)-www.terumomedical.com, Microport Scientific (China)-
www.microport.com, and W.L. Gore & Associates (U.S.)-www.gore.com

18. The lion’s share of the vascular stent market is
concentrated amongst the same major players in the
coronary stent market, however Boston Scientific,
Medtronic, and Microport Scientific market the most
diverse and comprehensive product lines of vascular stent
& endovascular grafting solutions. Additionally vascular
stent solutions evolve with drug-eluting vascular stents,
more versatile vascular angioplasty and stent placement,
as well as endovascular grafts for aortic bifurcations.
Vascular Stent & Endovascular Graft Products by Manufacturer
Abbott
Laboratories
Boston Scientific Medtronic Corp. Terumo Medical Biosensors Microport Scientific Biotronik Inc.
Vascular Stent -
Carotid
RX Acculink- 1st-to-
market for carotid
stents
WALLSTENT-
Monorail
Endoprosthesis
Vascular Stent-
Iliac
Omnilink Elite-
expandable stent
system
EPIC-self-expanding
stent system
Vascular Stent-
Femoral Arteries
Innova-self-
expanding stent
system
Misago RX-self-expanding
peripheral stent (for
superficial femoral artery &
proximal popliteal artery)
Biomatrix Flex-
Infrapopliteal
Astron-Lower-limb
arteries (Femoropopliteal
& Infrapopliteal), Astron
Pulsar - Gold-plated,
Pulsar-35 (Suprafemoral)
Endovascular
Grafts (AAAs &
TAAs)
Absolute Pro- self-
expanding stent
system
WALLSTENT-
Endoprosthesis
Endurant II-AAA,
Valiant-TAA, Talent-
TAA
Hercules T-
Transthoracic,
Hercules B-
Bifurcated Graft
System, Aegis
Bifurcated Stent
Graft System
Vascular Drug-
Eluting Stents
Biomatrix Flex-
Infrapopliteal
(Biolimus A9-
proprietary)

19. • While stent technology has become very effective for treating patients suffering from
cardiovascular disease, and even raising the bar in terms of outcomes, many clinical challenges
persist. These include speed-to-repair, complex lesions, treating complete coronary
blockages, and making image-guided stent placement routine, which today IT IS NOT;
one of the keys to long-term stent treatment success.
Summary: Why Zurn’s AARA or Biocompatible Stent is Much Better!
• Precise stent deployment: Robotic Assisted Surgery is fully-integrated into the AARA.
• Limitless anatomical placement of Bio-compatible stents: Stenting will be possible &
effective in the most difficult anatomical areas such as small brain capillaries, below-the-knee
(infrapopliteal) arteries, tortuous vessels, and vessel bifurcations; this will provide new
treatment options for patients suffering from stroke-related diseases and limb ischemia, both
of which can be life-threatening.
• Faster Time-to-Treatment (“Time is Brain”): The AARA can be deployed more quickly than
wire-catheter-based stent systems, since they are directly injected into the blood-stream and
navigated to the lesion immediately; their untethered characteristic negates the need to
scale a guidewire to a French Catheter, which can delay stent deployment and care.
• Faster Patient Recovery & Healthcare Cost Savings: Better stent placement offered by
AARA means significantly reduced adverse effects (lower risk of thrombus formation, less
endothelial damage), and hence a shorter hospital length-of-stay (LOS) for the patient.
The Artery Repair Apparatus is a Superior Solution
over existing stent technologies. It will come to be
known as a disruptive clinical solution, as it takes a
REVOLUTIONARY approach to vessel support and
repair. Namely, the integration of Robotic Assisted
Surgery (RAS) and its many accompanying
advantages & benefits.

20. Professional Background:
Clifford M. Thornton, Marketing
& Executive Support
• Highly competent and experienced in Cardiac Diagnostics (specialized in echocardiography / cardiac
sonography) and related knowledge on heart diseases (including cardiomyopathies)
• Certified Cardiovascular Technologist, Sanford-Brown Institute, 2004
• Registered Diagnostic Cardiac Sonographer (RDCS) – American Registry of Diagnostic Medical Sonographers (ARDMS) – Retired
status (was actively scanning from 2006 – 2014)
• Performed approximately 5,000 adult transthoracic echocardiograms (TTE) and 2,000 adult transesophageal echocardiograms
(TEE) (with performing cardiologist). Quality of studies rated by reading cardiologists most often in the good to excellent range.
• Developed strong and fluid working relationships with interventional and non-interventional cardiologists such as Michael S. Flynn,
M.D., FACC (was listed in Castle Connolly’s America’s Top Doctors – 2012-2013) and Julian Javier, M.D., Co-founder of Vascular
Device Partners (conducts first-in-Man medical device investigative studies).
• Successfully served as an echocardiography teacher & instructor for 4 years at a healthcare training school, helping students pass
their echo board exams and receiving very positive feedback from students.
• Worked independently and successfully as a contract echocardiographer for private cardiology practices, internist clinics, and
mobile ultrasound firms (in New Jersey, New York, Florida, Maryland, North Carolina, and Hawaii).
• Prior to entering the cardiac diagnostics field, acquired Fortune 500 experience as a Program
Manager and Business Analyst
• As a Program Manager for Lucent Technologies and then Avaya (was employed by them during the Avaya spin-off), served as an
integral member of the core teams for the product launches of mid-sized business communications systems, Merlin Magix R2.0
and IP Office R1.0.
• Served as a Business Analyst in MediaOne Group’s Market Strategy Development (MSD) Team, supporting directors on high-level
business plans for high-speed internet over coaxial cable, video-on-demand (VOD), and a FCC auction for Local Multi-Point
Distribution (LMDS) service or microwave-based wireless broadband communications. MediaOne Group evolved from USWest
Media Group and has since been acquired by Comcast Corporation.
• Served honorably in the United States Navy Reserve from 2002 – 2010 (in IRR from 2007 – 2010).
Voted Sailor of Quarter (April – June, 2004) for unit CART B-104, NWS Earle, Colts Neck, NJ
• Other academic credentials: B.S. Business Administration, Major: Marketing, New York University,
Leonard N. Stern School of Business, 1997, Made Dean’s List in 1996 (under Dean Frederick Choi)

21. Sources utilized for this presentation
• “Modeling Drug Release in Cardiovascular Eluting Stents”, Grassi G., Grassi M., Pontrelli G.,
Teresi L. in: Modelling Cardiovascular System and Mechanical Circulatory Support, Claudio
De Lazzari Ed., CNR, pp. 135-151, 2007
• University of Michigan Health System – Coronary, http://www.med.umich.edu/cardiac-
surgery/patient/adult/adultcandt/coronary_angioplasty.shtml
• Medscape: Peripheral Vascular Stent Insertion, Author: Dale K Mueller, MD; Chief Editor:
Karlheinz Peter, MD, PhD, http://emedicine.medscape.com/article/1839716-overview
• “What is robotic surgery with the da Vinci Surgery system?”,
http://www.laparoscopic.md/robotic
• University of Cincinnati Health, http://uchealth.com/services/robotic-surgery/patient-
information/benefits/
• Mayo Clinic, “Robotic Surgery”, http://www.mayoclinic.org/tests-procedures/robotic-
surgery/basics/definition/prc-20013988
• Aortic Stent Grafts – Global Analysis and Market Forecasts, MediPoint,
http://www.reportsnreports.com/reports/300725-medipoint-aortic-stent-grafts-global-
analysis-and-market-forecasts.html
• “EVAR Update: Competitors Stake Their Ground In a High-Growth Space”, Mary Thompson,
MedTech Insights, April 2013, http://www.nea.com/uploads/files/employee/TriVascular.pdf
• “Endovascular Repair of Aortic Disease: A Venture Capital Perspective”, Seminars in
Interventional Radiology, 2009 Mar; 26(1): 56–66.,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036456/
• Interventional Cardiology & Peripheral Vascular Devices Market (Embolic Protection, Chronic
Total Occlusion, Atherectomy, Thrombectomy, IVUS, Angiography Catheters, EVAR Stent
Grafts, IVC Filters, Stents, Balloons and Accessories) - Forecasts to 2019”,
MarketsandMarkets
• “REBEL Bare Metal Stent Could Be A $200 Million Opportunity For Boston Scientific”, Forbes,
March 21, 2014

22. Sources utilized for this presentation
(Continued)
• CORONARY STENTS – GLOBAL ANALYSIS AND MARKET FORECASTS, GlobalData – MediPoint,
November 2014
• “Coronary stents: historical development, current status and future directions”, Oxford Journals,
February 2013
• MediPoint: Coronary Stents - US Analysis and Market Forecasts, November 2014
• “Coronary Stents and Noncardiac Surgery: Current Clinical Challenges and Conundrums”,
http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7141.2009.00044.x/full
• “Modeling Stented Coronary Arteries: Where We are, Where to Go”, Annals of Biomedical
Engineering, July 2013, Volume 41, Issue 7, pp 1428-1444,
http://link.springer.com/article/10.1007/s10439-012-0681-6
• “Novel design of drug delivery in stented arteries: a numerical comparative study”, Math Biosci
Eng. 2009 Jul;6(3):493-508, http://www.ncbi.nlm.nih.gov/pubmed/19566122
• “Below-the-knee Interventions”, Cardiovascular Intervental Radioly, 2013, 36:302–311,
http://www.cirse.org/files/files/SOP/2013/SoP_BTK%20Interventions_vanOverhagen_2013.pdf
• Abbott Laboratories, www.abbott.com, 2014 Annual Report
• Boston Scientific, www.bostonscientific.com, 2014 Annual Report
• Medtronic Corporation, www.Medtronic.com, 2014 Annual Report
• Terumo Medical, www.terumomedical.com, 2014 Annual Report
• “Elixir Medical’s Contrarian Play in Cardiology: Go Bioresorbable or Go Home”, The MedTech
Strategist, June 30, 2015, Vol. 2, No. 12